$15.58
+0.95 (+6.49%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where REPL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 observational · 1 expanded access
Held by 14 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, D. E. Shaw & Co., Inc., Artisan Partners Limited Partnership, MILLENNIUM MANAGEMENT LLC, +9 more) · FINRA short interest 3.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3NCT06887348observationalEvaluate the long-term safety of patients treated with an RPx product | — | Recruiting | Other: Observational study with no interventions | Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma | 50 | Dec 2030 | ≤ 1,595 d | 2026-01-12 |
| VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]NCT06264180Overall Survival (OS)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Biological: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab · Drug: Single-agent chemotherapy | Advanced Melanoma | 400 | 2030-09-30 | in 1,503 d | 2026-07-15 |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaNCT06581406Overall Survival (OS)Randomized · Open-label · Treatment | Phase 2/3 | Recruiting | Biological: RP2, Ipilimumab, Nivolumab | Metastatic Uveal Melanoma | 280 | Jan 2030 | ≤ 1,261 d | 2026-04-02 |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin MalignanciesNCT04349436Primary Objective for Patients with Locally Advances CSCC (laCSCC)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Biological: RP1, intra-tumoral injection, oncolytic virus | Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer | 69 | Jul 2029 | ≤ 1,077 d | 2026-04-22 |
| Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348Percentage of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Biological: RP1, nivolumab | Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma | 340 | Jun 2028 | ≤ 681 d | 2026-02-13 |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCNCT05733598Overall Response Rate per modified RECIST 1.1Non-randomized · Open-label · Treatment | Phase 2 | Recruiting | Biological: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy | Hepatocellular Carcinoma, Biliary Tract Cancer | 60 | 2027-12-01 | in 469 d | 2026-04-02 |
| Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursNCT04735978Incidence of dose limiting toxicities (DLTs) during the DLT periodNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: RP3, Nivolumab | Advanced Solid Tumor | 123 | 2026-11-30 | in 103 d | 2026-02-27 |
| Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsNCT04336241Percentage of adverse events (AEs)Non-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: RP2, nivolumab | Cancer | 36 | 2026-10-31 | in 73 d | 2026-02-27 |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerNCT04050436Objective Response Rate (ORR) according to blinded independent reviewRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Cemiplimab · Biological: RP1 | Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma | 231 | Sep 2025 | — | 2025-01-27 |
| Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNNCT05743270LA Cohort: Progression-free SurvivalRandomized · Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor decision | Biological: RP3, nivolumab · Other: CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel | Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 0 | 2026-03-01 | — | 2025-03-11 |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCNCT05733611Objective Response Rate (ORR)Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business reasons. | Biological: RP2, RP3, atezolizumab, bevacizumab | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 5 | 2025-08-18actual | — | 2026-02-02 |
| An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced MelanomaNCT06590480expanded access | — | No longer available | Biological: RP1, Nivolumab | Advanced Melanoma | — | — | — | 2025-12-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19